-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 1, Huadong Medicine announced that the company’s subsidiary Sino-American Huadong obtained the Japanese SCOHIA Phase I clinical product SCO-094 (a dual agonist of GLP-1R and GIPR targets for the treatment of type 2 diabetes, obesity, and non- Alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) such as China, South Korea, Australia and so on.
On June 1, Huadong Medicine announced that the company’s subsidiary Sino-American Huadong obtained the Japanese SCOHIA Phase I clinical product SCO-094 (a dual agonist of GLP-1R and GIPR targets for the treatment of type 2 diabetes, obesity, and non- Alcoholic steatohepatitis and other diseases) have exclusive development, production and commercialization rights in 25 Asia-Pacific countries and regions (excluding Japan) such as China, South Korea, Australia and so on.